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Background:  Pneumonia  and  gastroenteritis  are leading  causes  of  vaccine-preventable  childhood  mor-
bidity and  mortality.  Malawi  introduced  pneumococcal  conjugate  and  rotavirus  vaccines  to  the
immunisation  programme  in  2011  and  2012,  respectively.  Evaluating  their  effectiveness  is vital  to ensure
optimal  implementation  and justify  sustained  investment.
Methods/Design:  A  national  evaluation  platform  was  established  to determine  vaccine  effectiveness
and  impact  in Malawi.  Impact  and  effectiveness  against  vaccine-type  invasive  pneumococcal  disease,
radiological  pneumonia  and rotavirus  gastroenteritis  are  investigated  using  before-after  incidence  com-
parisons  and  case-control  designs,  respectively.  Mortality  is  assessed  using  a prospective  population
cohort.  Cost-effectiveness  evaluation  is nested  within  the  case-control  studies.  We describe  platform
characteristics  including  strengths  and  weaknesses  for conducting  vaccine  evaluations.
Discussion:  Integrating  data  from  individual  level  and  ecological  methods  across  multiple  sites  provides
comprehensive  information  for policymakers  on  programme  impact  and  vaccine  effectiveness  includ-
ing  changes  in serotype/genotype  distribution  over  time.  Challenges  to robust  vaccine  evaluation  in
real-world  conditions  include:  vaccination  ascertainment;  pre-existing  rapid  decline  in mortality  and
pneumococcal  disease  in  the  context  of  non-vaccine  interventions;  and  the  maintenance  of  completeness
and  quality  of  reporting  at scale  and over  time.  In observational  non-randomised  designs  ascertainment
of  vaccine  status  may  be biased  particularly  in infants  with  fatal  outcomes.  In  the  context  of multiple  pop-
ulation  level  interventions  targeting  study  endpoints  attribution  of  reduced  incidence  to  vaccine  impact
may  be ﬂawed.  Providing  evidence  from  several  independent  but  complementary  studies  will  provide
the  greatest  conﬁdence  in  assigning  impact.  Welcome  declines  in  disease  incidence  and  in  child  mortality
make  accrual  of required  sample  sizes  difﬁcult,  necessitating  large  studies  to detect  the  relatively  small
Abbreviations: ARIa, cute respiratory infection; DSSd, emographic surveillance system; EPIe, xpanded program on immunization; GAVIg, lobal alliance for vaccines and
mmunization; IMCIi, ntegrated management of childhood illness; IPD, invasive pneumococcal disease; MEOm,  onitoring & evaluation ofﬁcer; NITAGn, ational immunisation
echnical advisory group; PCVp, neumococcal conjugate vaccines; PCV13, 13-valent pneumococcal conjugate vaccine; QECH, Queen Elizabeth Central Hospital; RV1m,
novalent rotavirus vaccine; WHO, World Health Organization.
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but  potentially  signiﬁcant  contribution  of  vaccines  to  mortality  prevention.  Careful  evaluation  of  vaccine
effectiveness  and impact  in  such  settings  is  critical  to  sustaining  support  for vaccine  programmes.  Our
evaluation  platform  covers  a large  population  with  a high  prevalence  of  HIV and malnutrition  and  its
ﬁndings  will  be relevant  to other  settings  in  sub-Saharan  Africa.
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. Background
Key to reducing child mortality in developing countries has been
he recent introduction of pneumococcal conjugate and rotavirus
accines [1]. Their incorporation into routine infant schedules
equires robust evidence from randomised efﬁcacy trials. Demon-
trating subsequent effectiveness and impact is challenging but
ssential for optimal implementation of these vaccines and sus-
ained investment [2].
Pneumococcus is a leading cause of pneumonia, meningitis and
acteraemia [3]. In clinical trials pneumococcal conjugate vaccines
PCV) were extremely efﬁcacious at preventing serious vaccine
erotype disease [4–6]. In low disease burden high income coun-
ries, PCV have led to major public health beneﬁts through direct
ffects and through herd immunity [7]. However, given differ-
ng epidemiology of pneumococcal transmission and exposure and
accine scheduling in resource-poor settings and higher prevalence
f malnutrition and HIV, vaccine effectiveness may  differ. Further-
ore, in several populations the overall beneﬁt of PCV has been
ffset by an increase in non-vaccine serotype disease and doubts
emain over the efﬁcacy of the vaccine against some serotypes [8,9].
Rotavirus is the principal cause of severe diarrhoea globally and
 major contributor to diarrhoeal deaths in the developing world
10]. Trials of oral rotavirus vaccines in high and middle income
ountries demonstrated high efﬁcacy (>85%), with evidence of sub-
tantial public health impact demonstrated by post-introduction
urveillance studies [11]. In low income countries these vaccines
how lower efﬁcacy [12,13]. A randomised trial of rotavirus vaccine
onducted in Malawi found 49% efﬁcacy [12], lower than in other
tudies [14,15]. Nonetheless, given the much higher disease burden
nd mortality, rotavirus vaccination has the potential to contribute
o greater absolute improvements in child survival, particularly if
ndirect effects are apparent.
PCV and rotavirus vaccine were recommended by the World
ealth Organisation (WHO) in 2007 and 2009 respectively and
ubsequently became eligible for Gavi Alliance support for low
ncome countries [16,17]. Malawi is among the poorest and most
ensely populated countries in Africa with a high burden of under-
utrition, HIV, malaria, pneumonia and diarrhoea [18]. Increasing
IV prevalence among women age 15–49 of 13.3% in 2004 [19]
o 22.7% in 2010 [20] led Malawi to adopt Option B+ (whereby all
IV-positive pregnant or breastfeeding women commence lifelong
ull antiretroviral therapy regardless of clinical or immunological
tage) in 2011 [21,22]. Under 5 mortality is decreasing (79 per
housand live births in 2010) possibly due to increased birth spac-
ng, antiretroviral roll-out, improved nutrition, sanitation and case
anagement, placing Malawi on track to meet the fourth Millen-
ium Development Goal of reducing child mortality [20]. With
AVI support, 13-valent pneumococcal conjugate vaccine (PCV13)
as introduced into the national immunisation programme in
ovember 2011 as a three-dose schedule (6, 10 and 14 weeks) with
 catch-up dose in the ﬁrst year of introduction for all infants <12
onths old. Monovalent rotavirus vaccine (RV1) was introduced in
ctober 2012 on a WHO  recommended two-dose schedule (6 and
0 weeks).Surveillance for invasive pneumococcal disease (IPD) or
otavirus acute gastroenteritis exists elsewhere in Africa, including
he Gambia, South Africa, Ghana and Kenya amongst others [23,24].hed  by Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
Malawi is notable for being the only country in which PCV13 was
introduced to a pneumococcal vaccine naïve population without
a catch-up campaign after the ﬁrst year of life, and for investi-
gating the impact of both PCV and RV1 on infant mortality. We
describe the methods of a nationwide surveillance platform that
has been established to evaluate pneumococcal and rotavirus vac-
cine impact and effectiveness and consider the platform’s strengths
and weaknesses.
2. Methods
2.1. Study design
In collaboration with the Ministerial National Immunisation
Technical Advisory Group (NITAG) [25], a national vaccine eval-
uation programme for vaccine-preventable endpoints has been
established in Malawi to determine the population impact of new
vaccines on mortality and morbidity. Several interlinked epidemi-
ological methods have been used (Table 1):
1. Sentinel surveillance at one rural and one urban site to
investigate changing disease incidence and distributions of S.
pneumoniae serotypes and rotavirus genotypes.
2. Matched case-control studies of direct PCV effectiveness against
IPD and against radiological pneumonia among vaccine age-
eligible children using age-neighbourhood matched community
controls selected by random walk.
3. Matched case-control study of indirect PCV effectiveness against
IPD in adults living with vaccine age-eligible children compared
with community based adult controls also living with vaccine
eligible children.
4. Matched and unmatched case-control studies of RV1 effec-
tiveness against severe acute rotavirus gastroenteritis
using age-neighbourhood matched community controls
and unmatched hospitalised rotavirus test-negative controls
respectively [26–28].
5. Population based cohort study to measure <5 years and post-
neonatal infant all-cause and disease-speciﬁc mortality by
vaccine status [29].
6. Cost-effectiveness studies from a societal, health care provider
and household perspective collecting comprehensive itemised
costing of actual costs incurred [30].
Case deﬁnitions, screening criteria and investigations are shown
in Tables 2 and 3. Universally issued subject- held medical records
(health passports) which contain the vaccination records are inter-
rogated for vaccination status.
2.2. Sites and populations under surveillance
The northern, central and southern regions of Malawi all partic-
ipate in surveillance; the northern (Karonga) and central (Mchinji)
sites are rural locations. The southern site (Blantyre) is a largepenumbra, so surveillance is representative of the entire popula-
tion and demography of Malawi (Fig. 1). The mortality cohort study
is located in the northern and central regions, while the morbidity
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Table  1
Summary of study details.
Study Design Primary endpoint (see also
Table 3)
Sample size Study site Recruitment to date Anticipated
completion
1 Sentinel surveillance Pneumococcus:
• Serotype speciﬁc incidence of
invasive pneumococcal disease
•  Relative serotype abundance
in carriage
• Clinical and radiological
pneumonia
Rotavirus: Genotypic speciﬁc
incidence of clinical
gastroenteritis
Not applicable Blantyre (IPD)
Blantyre & Karonga
(carriage, pneumonia,
rotavirus)
Not applicable Ongoing
2a  Matched case-control studies
of direct PCV effectiveness
against IPD
Odds ratio of vaccine receipt
among cases and matched
controls
47 VT IPD Blantyre 20 IPD Uncertain
2b  Matched case-control studies
of direct PCV effectiveness
against radiological pneumonia
Odds ratio of vaccine receipt
among cases and matched
controls
311 RCP Blantyre & Karonga 855 clinical
pneumonia, 180 RCP
2016
3  Matched case-control study of
indirect PCV effectiveness
against IPD in adults living with
vaccine age-eligible children
compared with community
based adult controls also living
with vaccine eligible children
Odds ratio of vaccine receipt
among age-eligible infants
living in household of adult
cases and controls
311 Blantyre Abandoned
4  Matched and unmatched
case-control studies of RV1
effectiveness against severe
acute rotavirus gastroenteritis
using community controls and
hospitalised rotavirus
test-negative controls
respectively
Odds ratio of vaccine receipt
among cases and matched
community controls
Odds ratio of vaccine receipt
among cases and test-negative
diarrheic controls
102 Blantyre & Karonga 109 Completed [28]
5 Population based cohort study
to measure <5 years and
post-neonatal infant all-cause
and disease-speciﬁc mortality
by vaccine status
Hazard ratio of all-cause and
cause-speciﬁc post-neonatal
infant mortality, by vaccine
receipt.
38,213 Mchinji & Karonga 34,119 PCV13 eligible
25,238 RV1 eligible
2016
6  Cost-effectiveness studies Cost per disability adjusted life
year saved
88 for each
vaccine
Blantyre & Karonga 530 Completed
VT = vaccine type, IPD = invasive pneumococcal disease, RCP = radiographically conﬁrmed pneumonia, PCV13 = 13-valent pneumococcal conjugate vaccine, RV1 = monovalent
rotavirus vaccine.
Table 2
Screening criteria for clinical syndromes.
Clinical syndrome Screening criteria Investigation performed
Gastroenteritis History of 3 looser than usual stools in 24 h Stool collection for rotavirus EIA
Pneumonia
(IMCI-deﬁned)
Raised respiratory rate for age AND any of: history of
cough or difﬁculty breathing
Nasopharyngeal swab with serotyping of identiﬁed
pneumococci
Chest X-ray
Severe pneumonia Pneumonia AND any of: chest wall indrawing or nasal
ﬂaring or grunting
Nasopharyngeal swab
Chest X-ray
Hypoxaemic
pneumonia
Pneumonia AND oxygen saturation <90% in air Nasopharyngeal swab
Chest X-ray
Very severe disease
(IMCI-deﬁned)
Any of:
History of convulsion, or
Impaired consciousness (on Blantyre Coma Score[40]),
or
Inability to feed, or
Vomiting everything, or
Weight for age ≤ −3 standard deviation from mean
Blood culture, with serotyping* of identiﬁed
pneumococci
If suspected meningitis: Lumbar puncture with
biochemistry, cell count, Gram stain and culture.
Purulent culture negative cases have lytA PCR.
If  associated pneumonia: Nasopharyngeal swab
Chest X-ray
Suspected sepsis Axillary temperature of at least 38 ◦C or less than 36 ◦C
AND Very severe disease; or
Any child with clinical suspicion of sepsis.
Blood culture, with serotyping* of identiﬁed
pneumococci
Malaria parasites screen
Suspected meningitis Bulging fontanelle, or
Stiff neck, or
Very severe disease with clinically suspicion of
meningitis, or
Suspected sepsis with clinical suspicion of meningitis
Lumbar puncture
Blood culture, with serotyping* of identiﬁed
pneumococci
* Serotyping by real time PCR and latex agglutination.
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Table 3
Primary endpoints for 4 vaccine effectiveness studies.
Primary endpoint Case deﬁnition
13-valent vaccine-
serotype
invasive
pneumococcal
disease
A suspected episode of septicaemia or meningitis with
conﬁrmed aetiology from CSF or blood by isolation of
pathogen or detection by PCR based methods.
WHO  deﬁned
radiological
pneumonia
Among children <5 years presenting to a study site
(either as outpatient or admitted inpatient), an episode
of IMCI-deﬁned (see Table 1) severe pneumonia or
pneumonia with very severe disease that also has
WHO  deﬁned endpoint consolidation as determined by
concordant X-ray reading among a panel of 3
especially trained readers.
Severe acute
rotavirus
gastroenteritis
New onset of gastroenteritis with a modiﬁed Vesikari
score ≥11 and with laboratory conﬁrmation of
rotavirus infection by enzyme linked immunosorbent
assay.
All-cause A reported death of a child aged 4 to 52 weeks from
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Fig. 1. Map  of Malawi. Areas highlighted represent the three study sites.
Studies by site: (1) Disease incidence and distributions of S. Pneumonia serotypes
and rotavirus genotypes. (2) Matched case-control studies of direct PCV effective-
ness against IPD and against radiological pneumonia using community controls. (3)
Matched case-control study of indirect PCV effectiveness against IPD in adults living
with vaccine age-eligible children. (4) Matched and unmatched case-control studies
of  RV1 effectiveness against severe acute rotavirus gastroenteritis using community
controls and hospitalised rotavirus test-negative controls, respectively. (5) Popu-post-neonatal
infant mortality
the deﬁned birth cohort capture population.
ase control studies and cost-effectiveness studies are located in
he northern and southern regions.
Northern Malawi: Supported by the London School of Hygiene
 Tropical Medicine, the Karonga Prevention Study demographic
urveillance system covering 35,000 individuals has operated in
aronga district since 2002 [31], health facility based pneumonia
nd diarrhoea surveillance in children operating since 2008 [31].
irths and deaths are reported monthly by a system of village key
nformants with verbal autopsies performed on all deaths. Health
assport vaccine records are reviewed at an annual census. Children
nder surveillance attend Chilumba Rural Hospital for medical care.
hose with Integrated Management of Childhood Illness (IMCI)
eﬁned severe pneumonia or gastroenteritis undergo chest X-ray
r stool collection for rotavirus testing, blood cultures are not per-
ormed. Karonga contributes to studies 1, 2 (but not IPD), 4 and 5
isted above. The study site provides robust data on historical rates
f disease and mortality prior to vaccine introduction.
Central Malawi: Mchinji district population was 456,516 persons
n the 2008 census, with an estimated live birth rate of 57 per 1000
opulation [32,33]. We  conducted a baseline census of Mchinji dis-
rict in March 2012. Ongoing prospective surveillance of over 2000
illages in the district is conducted for births and deaths or migra-
ion of children under 5 and women of child-bearing age. Village
nformants report vital events monthly, supported by enumera-
ors, supervised by monitoring and evaluation ofﬁcers (Fig. 2). Live
irths are followed to 1 year of age or death or emigration from the
istrict. All deaths reported by informants are veriﬁed and cause
f death determined by verbal autopsy. Vaccine status is obtained
rom the health passport at household visits at 4 and 12 month of
ge or following death. Mchinji contributes to the population based
ohort study listed above (study 5) and the primary endpoint of sur-
ival to 1 year. The site is coordinated by the Mai  Mwana Project,
ith support from University College London.
Southern Malawi: The Malawi-Liverpool-Wellcome Trust Clin-
cal Research Programme (MLW)  in Blantyre has surveillance for
PD spanning 13 years [3,22], and has extensively characterised
otavirus molecular epidemiology in the pre-vaccine era [34,35].
lantyre district numbered 1,001,984 persons at the 2008 cen-
us [32]. Queen Elizabeth Central Hospital (QECH) provides free
ealth services and is the principal referral centre [36]. Active case
nding at QECH paediatric emergency department and inpatient
ards enrols children with presumed sepsis, meningitis, acute gas-
roenteritis and severe respiratory illness, in whom blood culture,
umbar puncture, stool collection, chest radiography or nasopha-
yngeal swabs are performed per protocol. Blood culture is notlation based cohort study to measure under-5 and post-neonatal infant all-cause
and disease-speciﬁc mortality by vaccine status. (6) Cost-effectiveness studies from
societal, healthcare provider and household perspectives.
routinely performed in pneumonia unless a clinical suspicion of
sepsis exists. Anthropometry, vaccination status, and HIV status
are recorded [21]. This site is the platform for case-control stud-
ies of PCV13 effectiveness against vaccine type IPD and against
radiological pneumonia and of RV1 against severe rotavirus
N. Bar-Zeev et al. / Vaccine 33 (2015) 2637–2645 2641
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 listed above.
.3. Sample size estimates
Vaccine effectiveness case-control studies: Assuming 60% vacci-
ation coverage and control:case ratio of 4, the studies have 80%
ower to detect PCV13 effectiveness of ≥60% against vaccine type
PD with 47 vaccine age-eligible cases, ≥30% effectiveness against
adiologically conﬁrmed pneumonia with 311 cases, and effec-
iveness of ≥40% RV1 effectiveness against severe acute rotavirus
astroenteritis with 82 cases. Among adults, 311 vaccine type IPD
ases living with vaccine eligible children are needed to detect
30% indirect effectiveness.
Mortality cohort study: Assuming 70% vaccination coverage and
ccounting for a 12% loss to follow-up before 1 year of age, we aim
o recruit 38,213 live births over 2 years. This cohort provides 80%
ower at 5% one-tailed signiﬁcance to detect vaccine associated
mprovement in cause-speciﬁc post-neonatal infant mortality of
36% if baseline mortality is 15 per 1000 live births.
Cost-effectiveness: A sample size of 88 for each clinical
ndpoint (conﬁrmed rotavirus gastroenteritis, radiologically con-
rmed pneumonia) provides a precise estimator of the mean cost
f illness episode to within a margin ±10% [37].
.4. Implementation
Initial programme design involved close collaboration with the
inistry of Health, with speciﬁc inputs from the following ofﬁces:
xpanded Programme for Immunisation, Acute Respiratory Infec-
ion branch, IMCI branch and Epidemiology branch. Site visits were
onducted to assess research capacity. Regular meetings were held
ith the District Health Ofﬁces and Traditional Authorities. Study
versight is provided by the national coordinator based at MLW
lantyre, with site coordinators at each location. Regular site visits
ccur.chinji Mortality Cohort Study.
Study instruments were translated to Chichewa and Tumbuka.
Piloting took one month in Karonga, nine in Mchinji and two in
Blantyre. Surveillance for rotavirus gastroenteritis commenced in
August 2011 in Karonga and January 2012 in Blantyre, and for child
mortality in Mchinji in March 2012. Case control studies for IPD and
rotavirus commenced on the dates of vaccine introduction, but for
radiological pneumonia commencement was  in September 2013,
approximately 23 months after vaccine introduction.
2.5. Capacity building and health system integration
All studies have dedicated employed staff. Clinical staff were
trained in IMCI clinical management, Good Clinical Practice and
formally qualiﬁed as HIV testers and counsellors. Training in pae-
diatric radiological pneumonia standards was done against a WHO
deﬁned panel of standard ﬁlms [38]. WHO  verbal autopsy training
was undertaken in Mchinji and Karonga. Sensitisation on child-
hood immunisation of community leaders and health care staff was
undertaken. Review and feedback on quality of recording in vacci-
nation centre registers was also conducted. Data are shared with
the NITAG in which senior study staff are members, and Ministerial
NITAG members are on the platform’s steering committee.
2.6. Physical resources
Field: Coordination of activities across distant sites with poor
accessibility demanded a robust motorbike and bicycle based trans-
port infrastructure and regular site visits by supervisors to local
ﬁeld teams for scheduled data monitoring visits.
Laboratory: MLW  has an external quality assured microbiology
laboratory. Stool specimens received in Karonga are transported
to MLW  for further processing. Rotavirus status is determined
by enzyme linked immunosorbent assay (RotacloneTM, Merid-
ian Bioscience, Cincinnati). Rotavirus genotyping is done using
hemi-nested multiplex RT-PCR [39]. Pneumococcal quantiﬁcation
is performed using lytA PCR, while serotyping of carriage specimens
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rom Karonga and Blantyre and of invasive isolates from Blantyre is
erformed using triplex PCR and latex agglutination [40]. HIV status
f all children participating in studies 1, 2, 3, 4 and 6 is determined
n accordance with national guidelines [21].
Radiology: Chest X-rays from Blantyre and Karonga are stored
igitally according to a standardised protocol. Digital ﬁles are
eviewed at each site and then centrally by a trained panel.
.7. Data management
Data management has ensured harmonised linkage among the
ites, whilst integrating with existing legacy systems [41]. Data are
aptured on paper forms and entered to a relational Structured
uery Language database, with embedded data checks. In Mch-
nji paper forms are reviewed, scanned and entered. Timeliness is
ritical since subsequent contacts with subjects are automatically
riggered by the database. Verbal autopsy data are captured using
urpose built Visual Basic (Microsoft) platform. Similar systems
ccur in Karonga. Data cleaning, merging, logging and archiving
s undertaken weekly by a dedicated team, whose performance is
onitored. Subject recruitment by endpoint is reported at each site
nd is reviewed regularly by the study steering committee.
.8. Quality assurance activities
For valid ascertainment of vaccine status, the health passport is
eviewed upon each contact with participants. Passport images are
canned and digitally archived. In Karonga, digital capture occurs
or all cases and a random selection of children in the DSS. In
chinji, cluster sampling by catchment area is undertaken and a
epresentative sample is imaged and archived. Vaccination records
re checked against the local health centre vaccination register.
arental verbal report is also obtained for all children. Discrepan-
ies are resolved on the basis of rules deﬁned a priori in the study
rotocol. In case of missing passports, particularly among deceased
nfants, vaccination registers are cross checked. In Mchinji, inter-
iews are conducted quarterly with a sub-set of mothers following
accination visits to conﬁrm whether the child received the number
f vaccine doses that are recorded in the health passport.
.9. Programme performance indicators
Recruitment and protocol compliance are reviewed weekly in
lantyre, and monthly in Karonga and Mchinji. Observed event
ates are compared to long term expected rates and possible
nder-ascertainment is investigated by detailed review. Contigu-
us periods of suspected under-reporting will trigger the central
atabase to issue a warning and restorative ﬁeld activities under-
aken to collect missing data.
.10. External evaluation
Initial study protocols were reviewed by an external scientiﬁc
anel on behalf of the Wellcome Trust. Subsequent formal regu-
ar external review of protocol compliance is provided by visiting
pidemiologists (separate from study co-investigators) from the
enters for Disease Control and Prevention, Atlanta.
.11. Ethics
Community approvals from Traditional Authorities and Com-
unity Health Management Teams were obtained prior to study
mplementation and regular feedback of study progress is given.
nformed written consent is obtained from parents for case-control
tudies. Verbal consent is obtained for vital events surveillance3 (2015) 2637–2645
and verbal autopsy. Ethical approval was provided by the Malaw-
ian National Health Sciences Research Committee and University
of Malawi Research Ethics Committee, and by the University of
Liverpool and London School of Hygiene & Tropical Medicine.
3. Discussion
Maintaining high quality real world surveillance at large scale is
challenging [42]. We  outline the strengths and weaknesses of our
vaccine evaluation platform.
3.1. Strengths
Incorporating established large-scale population based surveil-
lance, the program covers a very large population, spanning urban,
peri-urban and rural settings. It has the capacity to determine vac-
cine effectiveness against mortality and morbidity in the context
of high rates of malnutrition and HIV. Because the studies include
rural and urban populations and span primary to referral level
care, the results are likely to be relevant to other countries in sub-
Saharan Africa or to low income countries elsewhere. Study sites
have strong community engagement and acceptance, and have high
quality track records in population epidemiology and clinical trials.
Strong laboratory surveillance capacity has been well established
at MLW  for over a decade, allowing pneumococcal serotype and
rotavirus genotype distributions to be described before and after
respective vaccine introductions [3,22].
In contrast to vaccine evaluations elsewhere, studies in Malawi
are occurring in a pneumococcal and rotavirus vaccine naïve popu-
lation, so can determine changes in pneumococcal serotype and
rotavirus genotype distribution for currently available vaccines.
Using multiple sites and methods provides complementary and
independent measures of vaccine effectiveness. Measures of effec-
tiveness against speciﬁc (e.g. IPD, RV proven gastroenteritis) and
less speciﬁc endpoints (e.g. radiological pneumonia, all-cause mor-
tality) are of major public health importance, and address questions
of value to policy makers. Nesting of multiple observational studies
examining different endpoints and spanning several sites pro-
vides more robust evidence of impact than any single study could
provide. Involvement of multiple agencies within the Ministry of
Health and its NITAG ensures integration of studies within exist-
ing government programmes thus engendering strong community
engagement and acceptability.
3.2. Challenges
Vaccine ascertainment is a major challenge (Table 4). Mea-
surement of vaccination status depends predominantly on health
passports, the availability of which may  be biased [43]. We  use
multiple methods to obtain recorded documentation of vaccina-
tion including home visits and cross-checking against health centre
vaccination registers. Retention of health passports among living
vaccine age-eligible children at 1 year of age is high (93% in Mchinji
and 85% in Karonga) [43]. There is however, a common practice in
Malawi to bury the health passport with the deceased child. We
obtain vaccination status as early as possible following schedule
completion and cross check against clinic registers in an attempt to
mitigate this problem.
Another challenge is determining vaccine effect in the setting of
multiple interventions. Malawi has seen a decline in pneumococ-
cal disease and in infant and child mortality over the past decade
[3,20,44]. Attributing any observed reduction in morbidity or mor-
tality to vaccine introduction, compared with the historical trend
is difﬁcult. Multiple government and non-government funded
interventions have been implemented in Malawi. In Karonga for
example, large scale sanitation efforts were implemented around
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Table  4
Challenges to valid vaccine evaluation at scale in Malawi, their potential impact and strategies to mitigate these.
Challenge Potential impact Mitigation strategies
Differential vaccine status
ascertainment
• Reduce power if rely solely on
written record.
• Potential bias if rely also on parental
recall
• Early ascertainment by study staff
• Community sensitisation on importance of record retention
•  Cross checking against vaccine clinic records
Multiple concurrent interventions • Reduce apparent VE because
unvaccinated children are protected
• Bias in ecological before-after designs
• Matching by neighbourhood
•  Recording other concurrent interventions and adjusting in analysis
•  Adjustment for prevalence of HIV, malaria and malnutrition
High  vaccine coverage • Unvaccinated children differ to
general child population
• Commence studies soon after vaccine introduction
• Measure and adjust for postulated measurable confounders
Care  seeking behaviour and differential
ascertainment of disease outcome
• Bias for ecological designs • Independent veriﬁcation using alternate data sources of differences
in  care seeking over time
• Propensity scoring
Decline in disease incidence prior to
vaccine introduction
• Attribution to vaccine of further
declines post vaccine introduction is
difﬁcult
• Time series methods
•  Consistency of results across study designs and study sites
• “Dose-response” in decline in incidence with respect to increasing
coverage
•  Extreme caution in causal attribution
Rapid decline in disease following
vaccine introduction
• Insufﬁcient case accrual making
case-control design unachievable
• Reliance on before-after designs
•  Utilising secondary endpoints (eg nasopharyngeal carriage rather
than invasive disease)
Assuring quality and consistency of
data collection at large scale
• May  introduce unmeasured bias • Close and frequent supervision
• Well deﬁned management and decision structure
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qhe introduction of rotavirus vaccine. Such interventions, their
cope and coverage affect the assessment of vaccine programme
mpact, and are difﬁcult to adjust for in analysis. The study meth-
ds primarily determine concurrent individual level assessment of
accine effectiveness by vaccine receipt, adjusting for individual
nd household exposure to communal interventions. Before and
fter analysis is also informative but attribution of any observed
hanges to vaccine alone is problematic.
Dealing adequately with confounders that increase the risk
f disease outcomes among unvaccinated children independent
f vaccine receipt is difﬁcult. As population coverage rises the
nvaccinated group becomes less representative of the gen-
ral population. We  measure socioeconomic and demographic
ovariates and adjust for these, but cannot deal with unmea-
ured confounders in the absence of randomisation. For incidence
nalysis we will conduct propensity scoring to help account
or ascertainment bias arising from differential care-seeking
ehaviours, and adjust for prevalence of HIV, malnutrition and
alaria [3,22,45].
Obtaining adequate sample size is a problem for some stud-
es. The decline in IPD makes achieving recruitment targets in
ase-control designs difﬁcult. This has led to the abandonment of
he case-control design to evaluate indirect effects (Study 3) and
ncreases the importance of ecological impact evaluation, but with
he latter design attribution of any incidence reduction to vaccine
ust be cautious. Given our observed baseline mortality was  lower
han was originally anticipated based on published estimates [20],
e will only be powered for high end decreases in all-cause mortal-
ty of greater magnitude than previously observed [6], increasing
he importance of having independent measures to provide con-
istency. In addition, the introductions of PCV13 and RV1, were
eparated by 11 months. Reductions in all-cause mortality achieved
y PCV13 will make detecting a beneﬁt of RV1 more difﬁcult, so
ause-speciﬁc mortality must be used which introduces a level of
ncertainty regarding the precision of causal determination by ver-
al autopsy. Although we will examine the impact of HIV on vaccine
ffectiveness, we are not adequately powered for deﬁnitive conclu-
ions regarding this important issue.
Completeness and quality of reporting is a continual chal-
enge. With over 1000 ﬁeld workers, heterogeneity in data
uality is inevitable. Supportive supervision, simple data collection•  Well deﬁned protocols and operating procedures
• Regular review of process measures and key performance indicators
instruments and automated performance target triggers are used
to improve data reporting by key informants and rectify under-
performing catchment areas. Long term sustainability of funding,
which is currently borne through competitive research funding
mechanisms, remains a challenge [46].
3.3. Interpretation
Maintaining large scale integrated multi-site epidemiologi-
cal research of high quality is challenging, requiring ongoing
investment in quality assurance of data collection. Reliance on
existing data systems like health passports and vaccine registers
is hampered by incomplete recording and by cultural factors, so
measuring vaccine status requires early proactive effort if observa-
tion bias is to be minimised. Formally imputing vaccine status to
deceased children is also subject to biases arising from our impu-
tation modelling assumptions. Community engagement within
existing socio-cultural systems is critical to the acceptability of
surveillance. Using multimodal methods of analysis that include
individual evaluation of effectiveness and ecological evaluation of
impact is important, particularly for the detection of indirect vac-
cine effect. Integrating several strands of evidence with consistent
results will provide greater conﬁdence in surveillance ﬁndings for
policy makers to act on. Other countries should of course consider
their own epidemiologic settings when evaluating the generalis-
ability of our results.
A long-term challenge facing this work and identiﬁed by the
Global Framework for Immunization Monitoring and Surveil-
lance is ﬁnancial sustainability [46]. Establishing the early public
health beneﬁts following vaccine introduction produces data to
advocate for broader vaccine use. Long term monitoring, though
more prosaic, is no less important since it maintains the qual-
ity of the vaccination programme. By building this surveillance
system collaboratively with the Malawi national immunization
programme, utilising established data sources, training local
health staff, and establishing locally feasible data management
systems we  have gone some way  to meet the Global Frame-
work requirements, but sources of continued funding will be
required.
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. Conclusion
Despite the challenges, evaluating how effective new vaccines
re in a real-world context is critical to encouraging vaccine intro-
uctions and sustaining vaccination programmes. Our large-scale
urveillance system provides a platform for evaluating impact of
CV13 and RV1 on infant mortality and morbidity from IPD, radi-
logically conﬁrmed pneumonia and severe gastroenteritis, and
ill determine cost-effectiveness in one of the world’s poorest
ountries. The system is powerful and of high quality but faces
onsiderable challenges, reﬂecting the real-world difﬁculties of
onducting high quality large scale research in infrastructure-poor
ettings. Demonstrating an impact on mortality (due 2016) and
orbidity (due 2015) will be important for the long term invest-
ent required to sustain vaccination programmes and to maximise
heir reach and delivery.
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